Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) have earned an average rating of “Buy” from the ten ratings firms that are presently covering the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $30.80.

Several research firms have weighed in on ADMS. Mizuho raised shares of Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating in a research report on Monday, June 13th. JMP Securities reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Piper Jaffray Cos. reissued an “overweight” rating and set a $44.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. Zacks Investment Research downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Finally, Noble Financial reissued a “buy” rating and set a $25.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 28th.

In other news, Director William W. Ericson bought 43,719 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The stock was purchased at an average cost of $14.75 per share, for a total transaction of $644,855.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Ix Lp Mdv bought 84,376 shares of the firm’s stock in a transaction that occurred on Tuesday, September 13th. The stock was purchased at an average price of $15.58 per share, with a total value of $1,314,578.08. The disclosure for this purchase can be found here. 31.79% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of ADMS. American International Group Inc. boosted its position in Adamas Pharmaceuticals by 57.9% in the second quarter. American International Group Inc. now owns 9,613 shares of the specialty pharmaceutical company’s stock valued at $146,000 after buying an additional 3,526 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new position in Adamas Pharmaceuticals during the second quarter valued at about $158,000. Highbridge Capital Management LLC purchased a new position in Adamas Pharmaceuticals during the second quarter valued at about $205,000. ProShare Advisors LLC boosted its position in Adamas Pharmaceuticals by 4.6% in the second quarter. ProShare Advisors LLC now owns 18,138 shares of the specialty pharmaceutical company’s stock valued at $275,000 after buying an additional 794 shares in the last quarter. Finally, Teachers Advisors Inc. boosted its position in Adamas Pharmaceuticals by 58.0% in the second quarter. Teachers Advisors Inc. now owns 26,961 shares of the specialty pharmaceutical company’s stock valued at $408,000 after buying an additional 9,894 shares in the last quarter. Hedge funds and other institutional investors own 74.65% of the company’s stock.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 4.02% during mid-day trading on Monday, hitting $16.58. 66,115 shares of the stock traded hands. The stock’s market cap is $363.58 million. The firm has a 50 day moving average of $15.78 and a 200 day moving average of $15.77. Adamas Pharmaceuticals has a 12 month low of $12.02 and a 12 month high of $31.84.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

5 Day Chart for NASDAQ:ADMS

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.